Clinical trials: Long Term Follow-Up
Infections, Papillomavirus
Follow-up Study to Evaluate the Long-term Efficacy of the HPV Vaccine (580299) in Healthy Young Adult Women in Brazil
Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. This Phase IIb study is designed to evaluate the the long-term efficacy, safety and immunogenicity of the 580299 HPV…
- Trial name
- NCT00518336
- Testing
- Blood sampling, Collection of cervical specimen, Cervarix
- Where
- 5 sites in Brazil
- Volunteers
- 433 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Left Ventricular Dysfunction Post Myocardial Infarction
Patient's Management Receiving Eplerenone Therapy
On a population of patients followed by an office-based cardiologist and treated with eplerenone, the objectives of the survey are: To describe the characteristics of the population treated.
- Trial name
- PERGAME (NCT01440049)
- Testing
- Prospective Observational
- Volunteers
- 160 people
- Sponsor
- Pfizer
Chronic Coronary Occlusion, Vascular Disease
XIENCE V® Everolimus Eluting Coronary Stent System USA Post-Approval Study (XIENCE V® USA Long Term Follow-up Cohort)
XIENCE V USA is a prospective, multi-center, multi-cohort post-approval study. The objectives of this study are To evaluate XIENCE V EECSS continued safety and effectiveness during commercial use in real world settings, and To…
- Conditions
- Chronic Coronary Occlusion, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis
- Trial name
- XVU-LTF (NCT01120379)
- Testing
- XIENCE V® EECSS
- Where
- United States
- Volunteers
- 5,034 people
- Sponsor
- Abbott Medical Devices
Hepatitis B, Chronic
A Follow-Up Study to WV19432, to Evaluate Long Term Post-Treatment Effects of PEGASYS (Peginterferon Alfa-2a(40KD))in Patients With HBeAg Positive Chronic Hepatitis B
This study is a long-term post-treatment follow-up to study WV19432, which evaluated the efficacy and safety of PEGASYS in patients with HBeAg positive chronic hepatitis B (CHB).Patients who received treatment with PEGASYS, and…
- Trial name
- NCT00927082
- Testing
- peginterferon alfa-2a [Pegasys]
- Where
- 31 sites in Australia, Brazil and 8 more
- Volunteers
- 383 people
- Sponsor
- Hoffmann-La Roche
Respiratory Disorders
A Long Term Follow-up Study up to 4 Years After Study Vaccination to Assess Immunogenicity and Safety of the Investigational Vaccine in Adults
The purpose of this long-term follow-up of a Phase I study is to evaluate the kinetics of the antibody response to NTHi-Mcat antigens and long-term safety, in subjects aged between 50-71 years at the time of enrolment in the…
- Trial name
- NCT03201211
- Testing
- Blood sampling, GSK biologicals investigational NTHi Mcat vaccine containing 10µg of PD, PE-PilA and UspA2., GSK biologicals investigational NTHi Mcat vaccine containing 10µg of PD, 10µg of PE-PilA, and 3.3µg of UspA2.
- Where
- 3 sites in Belgium
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Lung Cancer, Cancer
Bintrafusp Alfa Program Rollover Study
This study is designed to provide continuous access to treatment with bintrafusp alfa for eligible participants from ongoing bintrafusp alfa parent studies (NCT02517398, NCT02699515, NCT04246489, NCT03840915, NCT03631706…
- Trial name
- NCT05061823
- Testing
- Bintrafusp alfa
- Where
- 21 sites in United States, Belgium and 10 more
- Volunteers
- 22 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Acquired Thrombotic Thrombocytopenic Purpura
Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)
The objectives of this study were to evaluate long-term safety and efficacy of caplacizumab, to evaluate safety and efficacy of repeated use of caplacizumab and to characterize long-term impact of acquired thrombotic…
- Trial name
- NCT02878603
- Testing
- Caplacizumab, Standard of Care
- Where
- 45 sites in United States, Austria and 11 more
- Volunteers
- 104 people
- Sponsor
- Sanofi
Pemphigus Vulgaris, Pemphigus Foliaceus
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)
This was a prospective, multicenter, open label extension (OLE) trial on the efficacy, safety, patient outcome measures, tolerability, immunogenicity, PK and PD of efgartigimod PH20 SC in adult PV or PF participants, who…
- Trial name
- ADDRESS+ (NCT04598477)
- Testing
- efgartigimod PH20 SC, prednisone
- Where
- 127 sites in United States, Australia and 19 more
- Volunteers
- 183 people
- Sponsor
- argenx
Relapsing Remitting Multiple Sclerosis
Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409
Primary Objective: To evaluate long-term safety of alemtuzumab. Secondary Objectives: To evaluate long term efficacy of alemtuzumab.
- Trial name
- TOPAZ (NCT02255656)
- Testing
- alemtuzumab GZ402673
- Where
- 131 sites in United States, Argentina and 17 more
- Volunteers
- 1,062 people
- Sponsor
- Genzyme, a Sanofi Company
Papillomavirus Type 16/18 Infection, Cervical Intraepithelial Neoplasia
Human Papillomavirus (HPV) Vaccine Consistency and Non-inferiority Trial in Young Adult Women
The study will be extended for subjects who received all three doses of vaccine in Finland, Denmark and Estonia to determine long-term safety and immunogenicity of the HPV-16/18 vaccine.
- Trial name
- NCT00337818
- Testing
- Cervarix™
- Where
- Estonia
- Volunteers
- 770 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Arthritis, Rheumatoid
Long-Term Safety Follow-Up Of Subjects Previously Enrolled In Rheumatoid Arthritis Studies Of CP-690,550
The purpose of this study is to follow the health of subjects who have previously been enrolled in studies of CP-690,550 for treatment of their rheumatoid arthritis.
- Trial name
- NCT00414661
- Testing
- CP-690,550
- Where
- 72 sites in United States, Argentina and 19 more
- Volunteers
- 162 people
- Sponsor
- Pfizer
Anemia, Kidney Diseases
DELFT (Dynepo Evaluation of Long-Term Follow-Up Treatment)
This is a post-authorisation safety study to assess the incidence and severity of all pre-defined cardiovascular events in patients treated with DYNEPO, as well as to detect \& describe less common adverse drug reactions, and to…
- Conditions
- Anemia, Kidney Diseases, Renal Failure, Chronic, Kidney Failure, Chronic
- Trial name
- DELFT (NCT00664066)
- Testing
- DYNEPO (epoetin delta)
- Where
- 2 sites in Germany
- Volunteers
- 3 people
- Sponsor
- Shire
Postoperative Pain
Observational Study to Assess Long-Term Follow-Up of Breast Augmentation Subjects
A history and physical focused on clinical sequelae of breast implant rupture was completed by patients to assess long-term clinical sequelae of SKY0402 and its relation to the silicon shell.
- Trial name
- NCT01076686
- Testing
- Questionnaire and Physical Exam
- Volunteers
- 94 people
- Sponsor
- Pacira Pharmaceuticals, Inc
Growth and Development
Long-term Monitoring of Growth and Development of Pediatric Patients Previously Treated With Everolimus
The primary objective of CRAD001M2305 was to report the long-term effects of everolimus treatment on height, weight and sexual development (using Tanner Stages) in children and adolescents with Tuberous Sclerosis Complex…
- Trial name
- EXIST-LT (NCT02338609)
- Testing
- Everolimus
- Where
- 6 sites in United States, Belgium and 1 more
- Volunteers
- 15 people
- Sponsor
- Novartis Pharmaceuticals
Achromatopsia
Long-Term Follow-Up Gene Therapy Study for Achromatopsia CNGB3 and CNGA3
This is a longer-term follow-up study of patients with achromatopsia associated with defects in CNGA3 who participated in a clinical trial in which they received AAV-CNGA3 retinal gene therapy, or of patients with achromatopsia…
- Trial name
- NCT03278873
- Testing
- Prior exposure to AAV-CNGA3 or AAV-CNGB3
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 34 people
- Sponsor
- MeiraGTx UK II Ltd
Presbyopia
Long Term Follow-up of the VisAbility™ Micro Insert System for Presbyopic Patients
The objective of this study is to obtain an additional 36 months of safety and effectiveness data from all subjects who were implanted with the VisAbility™ Micro Insert in the VIS-2014 clinical trial.
- Trial name
- NCT03811249
- Testing
- VisAbility™ Micro Insert
- Where
- 13 sites in United States
- Volunteers
- 287 people
- Sponsor
- VisDura, Inc.
Birch Pollen Allergy
Follow-up of Study AN004T to Assess the Persistence of AllerT Efficacy During the 2nd to 4th Season After Treatment
Study aiming to evaluate the efficacy of a 2-month pre-seasonal treatment with an AllerT 50 µg or 100 µg maintenance dose administered in previous study AN004T in reducing symptoms of allergic rhinoconjunctivitis during the 2nd…
- Trial name
- NCT02143583
- Where
- 22 sites in Denmark, France and 5 more
- Volunteers
- 196 people
- Sponsor
- Anergis
Epilepsy, Partial
A Study Of The Safety And Efficacy Of Levetiracetam (Keppra®) (Ucb L059) In Children With Epilepsy
Open-label study to allow pediatric patients who have participated in prior Levetiracetam (Keppra®) studies to continue their treatment with adequate monitoring and standardized follow-up care until Levetiracetam (Keppra®) is…
- Trial name
- NCT00150709
- Testing
- Levetiracetam
- Volunteers
- 223 people
- Sponsor
- UCB Pharma
Asthma
Prevention of Asthma With Levocetirizine (36 Month Treatment) in Young Children Suffering From Eczema (Atopic Dermatitis) and Sensitized to Grass Pollen and House Dust Mite and Having Completed the Previous EPAAC Trial (NCT00152464)
Prolongation of the EPAAC™ trial - NCT00152464 (The Early Prevention of Asthma in Atopic Children). 36 months study to evaluate the efficacy and safety of levocetirizine (LCTZ) in preventing the onset of asthma in young atopic…
- Trial name
- NCT00160563
- Testing
- LEVOCETIRIZINE
- Where
- 51 sites in Australia, Belgium and 8 more
- Volunteers
- 207 people
- Sponsor
- UCB Pharma
Dengue, Dengue Fever
Long-Term Study of Hospitalized Dengue & Safety in Thai Children Included in a Tetravalent Dengue Vaccine Efficacy Study
The purpose of this study was to conduct a passive surveillance of hospitalized dengue cases in participants who participated in study CYD23 (NCT00842530).
- Conditions
- Dengue, Dengue Fever, Dengue Hemorrhagic Fever
- Trial name
- NCT01983553
- Where
- Thailand
- Volunteers
- 3,203 people
- Sponsor
- Sanofi Pasteur, a Sanofi Company